Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07308314
Recruiting Observational

Taining Golden Lake Comprehensive Chronic Disease Management Initiative

NCT07308314 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Observational
Started
2025-08-01
Last updated
2026-10-06

Condition(s) studied

Chronic DiseaseChronic Disease ManagementHypertensionDiabetes MellitusDyslipidemiasFrailtySarcopenia

Study summary

This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥18 years, male or female. * Resident of Taining County for ≥6 months and expected to remain in the county for at least the next 3 years. * Full civil capacity and able to understand study procedures. * Willing to voluntarily participate and provide written informed consent. * Able to complete baseline survey and follow-up visits. Exclusion Criteria: * Refusal to sign informed consent. * Severe psychiatric disorders or cognitive impairment preventing participation. * End-stage disease with expected survival \<1 year. * Long-term migrants (≥6 months per year outside the county), unable to guarantee follow-up. * Participation in other clinical studies that may interfere with this research.

Primary outcome measure(s)

  • Incidence of Major Adverse Cardiovascular Events (MACE) — Up to 36 months
    Composite outcome including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Events will be ascertained through active follow-up and confirmed using medical records and hospital discharge summaries.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian Recruiting

More First Affiliated Hospital of Fujian Medical University trials in China

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study Recruiting
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer Recruiting
Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes Recruiting
68Ga-FAPI PET/CT in Patients With Various Types of Cancer Recruiting
A Registered Cohort Study on Amyotrophic Lateral Sclerosis Recruiting

Other trials for the same condition

Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation Starting soon
Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia Recruiting
The Effect of Ablation Duration of Renal Denervation on Antihypertensive Efficacy Recruiting
Cohort Study in South China Active, not recruiting
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07308314 on ClinicalTrials.gov ↗ ← All trials in China